Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label Clinical Efficacy Study Defining Genomic Signatures That Correlate With Midostaurin Response in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Trial Profile

A Phase II, Open-Label Clinical Efficacy Study Defining Genomic Signatures That Correlate With Midostaurin Response in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Midostaurin (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms iCare4
  • Most Recent Events

    • 16 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 02 Oct 2018 Planned End Date changed from 1 Nov 2021 to 1 Jan 2022.
    • 02 Oct 2018 Planned primary completion date changed from 1 Nov 2020 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top